首页> 外文学位 >Design, synthesis and evaluation of core and substituent modified porphyrins as novel second generation photodynamic therapy sensitizers.
【24h】

Design, synthesis and evaluation of core and substituent modified porphyrins as novel second generation photodynamic therapy sensitizers.

机译:设计,合成和评估核心和取代基修饰的卟啉作为新型的第二代光动力疗法敏化剂。

获取原文
获取原文并翻译 | 示例

摘要

Photodynamic therapy (PDT) is a new area of treatment for cancer, which utilizes light, oxygen, and a sensitizer to generate a cytotoxic event such as the generation of singlet oxygen. One advantage of this type of therapy is that it targets only the tumor, through the localization of the sensitizer and the ability to apply light directly. PhotofrinxRTM, a PDT sensitizer approved by the FDA, is a mixture of oligomers of hematoporphyrin and has been successfully used with light for the treatment of bladder, neck, lung, and skin cancers.; PDT generates cytotoxic agents via two processes: (1) the excited sensitizer transfers an electron to yield a radical species that is cytotoxic and (2) the excited sensitzer reacts with oxygen to yield superoxide radical anion or singlet oxygen. Both of which are cytotoxic.; This research designed and prepared new porphyrin sensitizers. The first design element was the insertion of ethyne-linked phenyl substituents at the 5, 10, 15 and 20 position of the porphyrin. Ethyne linkers have been used as a donor-acceptor linker, molecular conjugator, molecular wires and also in the synthesis of porphyrin based PDT sensitizers. The results from the study showed that the linker did not affect the photophysical properties such as absorbance and molar absorptivity as well as excitation lifetimes and rates.; The second design element was the preparation of core-modified porphyrins in which pyrrole nitrogens have been replaced by one or two chalcogen atoms. This replacement, in the porphyrin, which was predicted to give a greater singlet oxygen yield and increase the wavelength of absorption relative to PhotofrinRTM, generating promising new photosensitizers for photodynamic therapy. The core-modified porphyrins gave longer wavelength absorption maxima (690 nm), high quantum singlet oxygen generation (>0.50), and were phototoxic to Colo-26 cells in culture (LD50 50 mug/ml) with minimal dark toxicity.
机译:光动力疗法(PDT)是治疗癌症的新领域,它利用光,氧气和敏化剂产生细胞毒性事件,例如产生单线态氧。这种疗法的一个优势是,通过敏化剂的定位和直接施加光的能力,它仅靶向肿瘤。 PhotofrinxRTM是FDA批准的PDT增敏剂,是血卟啉低聚物的混合物,已成功用于照明治疗膀胱癌,颈部癌,肺癌和皮肤癌。 PDT通过两个过程生成细胞毒剂:(1)激发的敏化剂转移电子以产生具有细胞毒性的自由基物质;(2)激发的敏化剂与氧反应产生超氧自由基阴离子或单线态氧。两者均具有细胞毒性。该研究设计并制备了新的卟啉敏化剂。第一个设计要素是乙炔连接的苯基取代基在卟啉的5、10、15和20位插入。乙炔连接体已用作供体-受体连接体,分子偶联剂,分子线,还用于合成基于卟啉的PDT敏化剂。研究结果表明,该连接剂不影响光物理性质,如吸光度和摩尔吸收率以及激发寿命和速率。第二个设计要素是制备核心修饰的卟啉,其中吡咯氮已被一个或两个硫族元素取代。相对于PhotofrinRTM,据预测,卟啉中的这种取代将产生更大的单线态氧产量并增加吸收波长,从而产生了有前景的用于光动力疗法的新型光敏剂。核心修饰的卟啉具有更长的最大波长吸收(690 nm),高的量子单线态氧生成(> 0.50),并且对培养中的Colo-26细胞具有光毒性(LD50 <50杯/毫升),且暗毒性最小。

著录项

  • 作者

    Stilts, Corey E.;

  • 作者单位

    State University of New York at Buffalo.;

  • 授予单位 State University of New York at Buffalo.;
  • 学科 Chemistry Organic.
  • 学位 Ph.D.
  • 年度 2000
  • 页码 131 p.
  • 总页数 131
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 有机化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号